Safety of monoclonal antibodies for the treatment of multiple sclerosis

@article{McGinley2017SafetyOM,
  title={Safety of monoclonal antibodies for the treatment of multiple sclerosis},
  author={M. McGinley and B. Moss and J. Cohen},
  journal={Expert Opinion on Drug Safety},
  year={2017},
  volume={16},
  pages={100 - 89}
}
  • M. McGinley, B. Moss, J. Cohen
  • Published 2017
  • Medicine
  • Expert Opinion on Drug Safety
  • ABSTRACT Introduction: Monoclonal antibodies are a potent therapeutic approach for relapsing-remitting multiple sclerosis. This group of medications comprises diverse mechanisms of action resulting in both shared and unique adverse effects. Areas covered: The major trials and safety profiles of natalizumab, alemtuzumab, daclizumab, rituximab, and ocrelizumab are discussed. While each drug has a unique safety profile, one of the potential safety concerns for all of these drugs is infection… CONTINUE READING
    20 Citations
    Nogo-A Antibodies for Progressive Multiple Sclerosis
    • 17
    • PDF
    HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab
    • 10
    Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: A Network Meta-Analysis
    • 16

    References

    SHOWING 1-10 OF 127 REFERENCES
    Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
    • 100
    Getting specific: monoclonal antibodies in multiple sclerosis
    • 70
    Emerging injectable therapies for multiple sclerosis
    • 30
    A link between long-term natalizumab dosing in MS and PML
    • E. Major, A. Nath
    • Medicine
    • Neurology: Neuroimmunology & Neuroinflammation
    • 2016
    • 21
    • Highly Influential
    • PDF
    Rituximab add-on therapy for breakthrough relapsing multiple sclerosis
    • 166
    Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
    • 55
    • PDF
    Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.
    • 312
    • PDF